Litcius/Paper detail

Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy

Toulsie Ramtohul, Victoire Lepagney, Claire Bonneau, Maxime Jin, Emmanuelle Menet, Juliette Sauge, Enora Laas, Emanuela Romano, Diana Bello-Roufai, Fatima Mechta-Grigoriou, Anne Vincent‐Salomon, François‐Clément Bidard, A. Langer, Caroline Malhaire, Luc Cabel, Hervé J. Brisse, A. Tardivon

2024Radiology34 citationsDOI

Abstract

A radiomics score derived from pretreatment perfusion MRI effectively predicted pathologic complete response in participants with early-stage triple-negative breast cancer following neoadjuvant chemoimmunotherapy.

Topics & Concepts

MedicineBreast cancerTriple-negative breast cancerReceiver operating characteristicNomogramNeoadjuvant therapyLogistic regressionArea under the curveNuclear medicineChemoimmunotherapyDynamic contrast-enhanced MRIBreast MRIStage (stratigraphy)Internal medicineRadiologyMagnetic resonance imagingCancerBiologyImmunotherapyPaleontologyMammographyRadiomics and Machine Learning in Medical ImagingMRI in cancer diagnosisMedical Imaging Techniques and Applications
Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy | Litcius